LeonaBio (LONA) Total Non-Current Liabilities (2019 - 2026)
LeonaBio (LONA) reported Total Non-Current Liabilities of $21.1 million for Q1 2026, down 66.54% on a QoQ basis from $63.0 million in Q4 2025.
LeonaBio (LONA) has 3 years of Total Non-Current Liabilities data on file, last reported at $21.1 million in Q1 2026.
- Quarterly Total Non-Current Liabilities changed N/A year-over-year to $21.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $21.1 million (changed N/A YoY) and the FY2025 annual result came in at $63.0 million, changed N/A from the prior year.
- Total Non-Current Liabilities eased to $21.1 million in Q1 2026 per LONA's latest filing, from $63.0 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $63.0 million in Q4 2025 and bottomed at $21.1 million in Q1 2026.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 7.32 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 4.05 Bn |
| 10 | LeonaBio | 181.52 Mn | 113.84 Mn | - | 21.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 21.07 Mn |
| Dec 31, 2025 | 62.96 Mn |
| Dec 31, 2019 | 3.86 Mn |